Outcomes for patients with high-risk large B-cell lymphoma (LBCL), defined by an International Prognostic Index (IPI) score ...
Patients with relapsed multiple myeloma treated with the immunotherapy teclistamab lived significantly longer and remained in remission far longer than those receiving standard therapies, according to ...
Patients with relapsed multiple myeloma treated with the immunotherapy teclistamab lived significantly longer and remained in ...
MajesTEC-9 randomized 593 patients (median age 70; median two prior lines) to teclistamab or investigator’s choice PVd or Kd; 80% lenalidomide-refractory, 85% anti-CD38–refractory. Interim analysis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results